XYREM Drug Patent Profile

When do Xyrem patents expire, and when can generic versions of Xyrem launch?

Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-one countries.

The generic ingredient in XYREM is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xyrem

A generic version of XYREM was approved as sodium oxybate by AMNEAL on September 10^th, 2025.

Summary for XYREM

International Patents:	34
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	29
Drug Prices:	Drug price information for XYREM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYREM
What excipients (inactive ingredients) are in XYREM?	XYREM excipients list
DailyMed Link:	XYREM at DailyMed

See drug prices for XYREM

Pharmacology for XYREM

Drug Class	Central Nervous System Depressant
Physiological Effect	Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity

Paragraph IV (Patent) Challenges for XYREM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYREM	Oral Solution	sodium oxybate	500 mg/mL	021196	1	2010-07-08

US Patents and Regulatory Information for XYREM

XYREM is protected by seven US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y

EU/EMA Drug Approvals for XYREM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma Ltd	Xyrem	sodium oxybate	EMEA/H/C/000593Treatment of narcolepsy with cataplexy in adult patients.	Authorised	no	no	no	2005-10-13
D&A Pharma	Hopveus	sodium oxybate	EMEA/H/C/004962Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.	Refused	no	no	no		2020-07-06

International Patents for XYREM

See the table below for patents covering XYREM around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5204685
South Korea	102239042
Denmark	3335708
Croatia	P20200215
Australia	779354
Israel	240874	מתן של גמא -הידרוקסיבוטיראט עם נשאי מונוקרבוקסילאט (Administration of gamma hydroxybutyrate with monocarboxylate transporters)
South Korea	20150125943

Supplementary Protection Certificates for XYREM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2932970	1890039-9	Sweden		PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
2465580	SPC/GB21/030	United Kingdom		PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221
0806968	SPC/GB07/011	United Kingdom		PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2203431	1590018-6	Sweden		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0579826	02C0041	France		PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
2380576	20C1048	France		PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729
2666774	202040029	Slovenia		PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF SODIUM SALT; NATIONAL AUTHORISATION NUMBER: EU/1/19/1420; DATE OF NATIONAL AUTHORISATION: 20200213; AUTHORITY FOR NATIONAL AUTHORISATION: EU

XYREM (sodium oxybate) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

Summary: XYREM (sodium oxybate) is the market-leading prescription for narcolepsy-associated cataplexy and excessive daytime sleepiness. Its sales trajectory has been shaped by (1) narcolepsy demand growth and formulary access, (2) branded-competition dynamics in sleep disorders, (3) payor controls on high-cost therapy, and (4) manufacturing and supply stability. Financial performance has also tracked changes in U.S. and ex-U.S. pricing, treatment uptake, and channel inventories typical of a chronic, high-acquisition-cost specialty CNS product.

---

What is XYREM and where does it sell?

Product: XYREM (sodium oxybate; immediate-release oral solution in divided doses).
Core indications:

• Narcolepsy with cataplexy
• Narcolepsy with excessive daytime sleepiness (EDS), where used in clinical practice alongside cataplexy

Key market footprint (practical commercial scope):

• Primary commercial geography: United States
• International: Commercialization exists in multiple markets, with revenue contribution dependent on country-specific pricing, reimbursement, and regulatory labeling structure.

Commercial model traits (affect sales behavior):

• Chronic, nightly administration
• Specialized distribution and payer management
• Tight safety-monitoring and REMS-like operational constraints (where applicable) that can affect refill timing and payer approvals.

---

How do market dynamics affect XYREM demand?

Narcolepsy prevalence and diagnosis rate

XYREM demand moves with:

• Patient diagnosis rates for narcolepsy
• Referral patterns to sleep specialists
• Adoption of guideline-consistent therapy for cataplexy and EDS

Because narcolepsy is often underdiagnosed, demand can show step-changes when awareness, diagnostic access, and payer recognition rise. Those changes typically drive incremental prescription volume rather than sudden shifts in per-patient intensity, since dosing is anchored to titration protocols and tolerability.

Formulary position and payer coverage

High-cost specialty CNS drugs are sensitive to:

• Formulary tiering (preferred vs non-preferred)
• Prior authorization and step edits
• Quantity controls and use of specialty pharmacies

For XYREM, market access has historically been a dominant driver of unit growth. When managed-entry protocols tighten, sales can flatten even if diagnosis improves.

Clinical differentiation and switching dynamics

XYREM’s sales sensitivity depends on the extent to which alternatives:

• Are perceived as easier to initiate or manage
• Have fewer administrative barriers
• Address cataplexy and EDS simultaneously

In practice, switching risk is most pronounced when:

• A competitor expands label reach for both cataplexy and EDS
• Payers prefer a lower net-cost option
• Patient or prescriber experience shifts based on tolerability or convenience

Specialty channel behavior

XYREM behaves like other high-cost chronic CNS products:

• Prescription timing tied to titration and adherence patterns
• Channel inventory cycles that can amplify quarter-to-quarter swings
• Reimbursement approvals that create lags between patient identification and first fill

These dynamics affect the observed sales “shape” even when underlying patient starts are stable.

---

What has driven XYREM revenue performance over time?

Primary revenue levers:

1. Prescription volume (patient starts and renewals)
2. Net pricing (rebates, discounts, and payer mix)
3. Geographic mix (U.S. share vs ex-U.S.)
4. Supply continuity (to avoid missed doses and lost refills)
5. Competitive and guideline pressure (therapy selection)

Typical quarterly financial trajectory drivers for XYREM-like therapies

• Early ramp: new patient starts plus payer onboarding and specialty pharmacy scaling.
• Mature phase: growth slows; volume becomes incremental and pricing becomes the main variability driver.
• Late-cycle: competition and payer pressure increasingly constrain net revenue growth.

For XYREM specifically, the financial trajectory has remained tethered to U.S. narcolepsy reimbursement durability and the ability to maintain payer access despite periodic competitive launches in sleep/cataplexy space.

---

How does XYREM compare to other narcolepsy and sleep-disorder drugs in market behavior?

XYREM competes in a market where payors balance:

• Efficacy in cataplexy and EDS
• Treatment convenience
• Administrative burden (prior authorization, REMS-like requirements)
• Net cost

Competitive comparison dimensions that matter to financial outcomes:

• Dual symptom coverage (cataplexy plus EDS)
• Initiation simplicity and titration tolerability
• Payer preference driven by net price and access rules
• Switching friction (patient persistence and prescriber comfort)

A competitor that improves convenience or payer alignment can pressure XYREM net revenue even if it does not fully displace it clinically, because payers influence the initial treatment and renewal cohorts.

---

What is XYREM’s financial trajectory pattern (growth, stability, or decline)?

Directionally: XYREM has largely followed a mature branded specialty pattern:

• Stability supported by persistent narcolepsy demand, ongoing patient renewals, and durable payer coverage in priority segments.
• Growth constraints from cost containment measures and competitive positioning as sleep-disorder formularies evolve.
• Periodic volatility from supply events, payer administration changes, and channel inventory dynamics.

In mature CNS specialty franchises, the strongest predictor of sustained topline is not label change alone; it is the product’s ability to maintain net coverage while resisting preference erosion in key managed-care contracts.

---

What role do reimbursement and pricing pressures play?

Net price is the key financial lever

For branded CNS drugs, list price is rarely the end of the story. Rebates, dispensing fees, and formulary contracting determine net revenue. XYREM’s trajectory should be read through:

• U.S. payer mix changes
• Rebate rate shifts
• Contract expirations and renegotiations
• Health plan moves to lower-cost alternatives or tighter PA criteria

PA and utilization controls

Payer controls typically show up as:

• Slower patient starts
• Higher denial rates or extended approval timelines
• Increased reliance on specialty pharmacy programs with additional documentation
• Reduced persistence in marginally adherent patients when administrative overhead rises

These affect sales even without clinical disadvantages for the drug.

---

How do supply and manufacturing constraints affect sales?

High-dose, chronic, controlled distribution products can show sales dents when:

• Manufacturing capacity tightens
• Component availability fluctuates
• Batch release timing delays refill cycles

In these cases, quarter-to-quarter revenue can dip even if demand is steady because patients experience treatment interruptions, delayed starts, or lost renewals.

---

What is the investment-relevant outlook for XYREM’s market and financial path?

XYREM’s near-to-mid-term outcome is governed by:

• Payer access durability in top narcolepsy patient segments
• Relative competitiveness versus branded and emerging options for cataplexy and EDS
• Net pricing and rebate environment
• Patient persistence tied to tolerability and nightly regimen adherence
• Regulatory and guideline stability in narcolepsy management

In mature branded CNS products, the base case usually hinges on maintaining net revenue per patient and volume persistence, with growth limited unless new access wins or significant clinical expansion appears.

---

Key Takeaways

• XYREM demand tracks narcolepsy diagnosis, specialist prescribing, and chronic treatment persistence rather than short-term trend drivers.
• Financial performance depends more on net pricing, payer coverage, and prior authorization behavior than on headline list price changes.
• Market share pressure is most likely when competitors improve convenience or payer alignment, especially where they cover both cataplexy and EDS.
• Sales volatility often reflects specialty channel timing and supply continuity, not shifts in core clinical need.
• Sustained revenue durability relies on preventing payer preference erosion and maintaining refill reliability in controlled distribution channels.

---

FAQs

1) What symptoms does XYREM treat that drive chronic prescribing?

XYREM is used for narcolepsy-associated cataplexy and excessive daytime sleepiness, supporting chronic nighttime dosing and ongoing renewals.

2) What is the main cause of quarter-to-quarter sales volatility for a specialty CNS product like XYREM?

Utilization management and specialty channel timing, including prior authorization lags and refill cycle impacts.

3) How do payers affect XYREM net revenue?

Through formulary tiering, rebate contracting, and prior authorization criteria that determine access for new starts and ongoing renewals.

4) Does XYREM face switching risk from competing narcolepsy therapies?

Yes, switching risk increases when competitors improve convenience and payer preference, particularly if they offer coverage for cataplexy and EDS with lower net cost.

5) What operational factor most directly impacts XYREM supply-driven sales changes?

Manufacturing and batch release continuity that determines whether patients can maintain expected refill schedules.

---

References

[1] U.S. Food and Drug Administration. XYREM (sodium oxybate) prescribing information. FDA.
[2] Jazz Pharmaceuticals. XYREM product information and label materials. Company website and SEC filings.
[3] IQVIA / EvaluatePharma branded specialty drug market dynamics (category reporting used for industry framing). IQVIA/EvaluatePharma reports.
[4] U.S. Centers for Medicare & Medicaid Services and payer policy documents relevant to specialty pharmacy authorization structures. CMS.